Covid: Dr Reddy's expects first lot of Sputnik V vaccine by May end

Dr Reddy's Laboratories, which has received approval from the Indian drug regulator for restricted emergency use of COVID-19 vaccineSputnik V,on Tuesday said it expects the first lot of stock from Russian Direct Investment Fund by May end.
In September 2020, Dr Reddys and RDIF entered into a partnership to conduct clinical trials of SputnikV, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the rights for distribution of the first 100 million doses in India.
Later, it was enhanced to 125 million.
"We are targeting to have the first batches imported by Q1, and are trying our best to have them by end-May," A Dr Reddy's spokesperson told PTI in an email reply.

Related Keywords

India , Russia , Pune , Maharashtra , Russian , Bharat , Kirill Dmitriev , Gamaleya National Research Institute Of Epidemiology , Serum Institute Of India , Russian Direct Investment Fund , Gamaleya National Research Institute , Bharat Biotech , Serum Institute , Domestic Manufacturing , Dr Reddys Laboratories , Sputnik V , Coronavirus , Coronavirus Vaccine , இந்தியா , ரஷ்யா , புனே , மகாராஷ்டிரா , ரஷ்ய , பாரத் , சீரம் நிறுவனம் ஆஃப் இந்தியா , ரஷ்ய நேரடி முதலீடு நிதி , பாரத் பயோடெக் , சீரம் நிறுவனம் , உள்நாட்டு உற்பத்தி , டாக்டர் ரேட்திச் ஆய்வகங்கள் ,